Flexion Therapeutics, Inc. has entered into a strategic manufacturing and supply agreement with Patheon for the manufacture of FX006, Flexion’s lead program. This agreement is in addition to Flexion’s existing manufacturing partnership with Evonik Corp. and creates redundant supply for FX006, a sustained-release steroid for the treatment of osteoarthritis entering Phase III development.   Patheon and Flexion will establish a dedicated manufacturing suite at Patheon’s specialt...